201107 CDISC ESUG-TC Trial Design

Report
Trial Design in the CDISC World
Albert Chau
26 July 2011
1
2
Agenda

How to construct Trial Design datasets
o

Challenges for new users
o
o

Relationships with other SDTM domains
Confusion of definitions/terms
Granularity
Case study in oncology
3
Trial Design Domains

Information about study design
o

No subject data
Describe the overall trial design and plan via data
representation
4
Trial Design Datasets






Trial Arms (TA)
Trial Elements (TE)
Trial Visits (TV)
Trial Inclusion /Exclusion (TI)
Trial Summary (TS)
Start thinking about this before you start the other
SDTM datasets!
5
Trial Summary (TS) Dataset



Summary of trial information
No link to subject-level data in SDTM
Common questions:
o
o
What need to be included?
Why are we generating this?
6
Trial Inclusion/Exclusion (TI)


Not subject-oriented
Link to IE domain
o
o

STUDYID, IECAT, IETESTCD, IETEST
Best to create TI first, before you tackle IE
Common questions:
o
o
o
How to truncate if >200 characters?
Protocol amendment: do we need to add to TI only the
changed criteria or all criteria?
Local amendment
7
TA / TE / TV datasets



A data representation on the different epochs,
arms and visit structure in the study
Where to start?
Is there a systematic approach?
8
Example 1 – Trial Design Schema
Drug A
Follow-up
Drug B
Follow-up
Screen
9
Epoch
Drug A
Follow-up
Drug B
Follow-up
Treatment
Follow-up
Screen
EPOCH
Screening
10
(Treatment
Strategy)
ARM
Arm / Treatment Strategy
2
Follow-up
Drug B
Follow-up
Treatment
Follow-up
Screen
Screening
1
Drug A
11
Arm / Treatment Strategy
Drug A
Follow-up
Drug B
Follow-up
Screening
Treatment
Follow-up
1
Screen
Drug A
Follow-up
2
Screen
Drug B
Follow-up
Screen
12
Trial Design Matrix
Screening
Treatment
Follow-up
A
Screen
Drug A
Follow-up
B
Screen
Drug B
Follow-up
13
TE (Trial Elements)

What are the elements?
o
Unique study cell values (=ELEMENT)
Screen
Drug A
Drug B
Follow-up
14
TE (Trial Elements)
Assign an element code (ETCD) to each value,
define the start of each element (TESTRL) and
end of each element (TEENRL or TEDUR)
ETCD
ELEMENT
TESTRL

SCRN
Screen
Informed Consent
A
Drug A
First dose of drug A
B
Drug B
First dose of drug B
FU
Follow-up
1 week after last dose of drug
15
Trial Arms (TA) Dataset




Go back to the Trial Design Matrix
1 study cell = 1 row of record in TA
So in our example we expect 6 rows of record
ARM / ARMCD
o
o

= Treatment Strategy
Not necessarily the same as the actual drug
names/codes
ETCD / ELEMENT
o
Must match up with the values in TE
16
TE -> SE (Subject Elements)

Shows the trial progress of each subject
o
o
Whether a subject passes through each element
Timing of each element
17
Trial Visit (TV) Dataset





Describe the planned visits in a trial
VISITNUM and TRSTRL is required
ARMCD expected
VISIT and VISITDY permissible
1 record per planned visit per arm
o
A “visit” may span over several days (eg screening
visit)
18
TV -> SV (Subject Visits)

Shows the actual visits of each subject
o
o

Compare against the scheduled/planned visits or
assessments in TV
Include unscheduled visits
Designation of VISITNUM becomes crucial
o
o
Whole number for planned visits
Decimals for unscheduled visits in SV – and slot into
right place
19
Challenges in 1 oncology study

Leukemia
o
o

Patients to receive:
o
o

Drug X (Days 1-4) is the current standard of treatment
Drug A (Days 1-7) is the experimental treatment
Drug A+X vs Drug X (1 course of treatment)
If patients on drug X not responding, then option to
“crossover” to drug A+X (1 further course)
Follow-up
o
o
Responders: Efficacy follow-up (+ post-remission
therapies where applicable)
Non-responders and relapse: Survival follow-up
20
Study schema
Efficacy FU
(q 1 months)
Drug A + X
Screen
Survival FU
(q 3 months)
Drug X
Drug A + X
21
Question 1 – what are the epochs?
Efficacy FU
(q 1 months)
Drug A + X
Screen
Survival FU
(q 3 months)
Drug X
Drug A + X
Screening


Treatment
Efficacy FU
1 Treatment epoch or separate into 2?
1 Follow-up epoch or separate into 2?
Survival FU
22
Question 2 – How many arms?
Efficacy FU
(q 1 months)
Drug A + X
Screen
Survival FU
(q 3 months)
Drug X
Drug A + X

For the patients on Drug X and then rollover to
Drug A+X – should this considered as a separate
“arm”?
23
Question 3 – Granularity of Elements

Do we model using “Treatment”+”Rest” or simply
“Treatment” (which includes rest period)?
Treatment
Rest
(Day 1 - 7)
(Day 8 – ??)
Treatment
(Day 1 - 37)


Length of “Rest” differs between patients
Do we need to distinguish between “Treatment”
and “Rest”?
24
Question 4 – Describing Trial Visits



How to number the visits, when you don’t know
how many visits there are up-front?
Don’t have to be consecutive numbers
Example:
o
o
o
o
1st course of treatment: Start with VISITNUM=11
Cross-over: Start with VISITNUM=51
Efficacy follow-up: Start with VISITNUM=201
Survival follow-up: Start with VISITNUM=501
25
Question 5 – Varying Trial Visits



During Efficacy Follow-up, patients can receive
“post-remission therapies”.
“Reset” follow-up clock from post-remission
therapies
How to model Trial Elements and Visits?
26
Question 5 – Varying Trial Visits

Suggestion:
o
o
o
o
o
Start with VISITNUM=201 for Efficacy Follow-up
Trial Element: Up to the next post-remission therapy
1st Post-Remission therapy: VISITNUM=250
2nd Post-Remission therapy: VISITNUM=300
etc
27
Question 6 – Post-remission therapies



For post-remission therapies in efficacy follow-up,
the choice is down to the treating physician
Can potentially be Drug X or any other
therapies
Should we create Trial Elements for the different
therapies?
Question 7 – Randomised but not
treated




Randomisation usually starts 1-2 days before
start of treatment due to logistic reason
What is the start and end of “Screen” and “Drug
A”/”Drug A+X” trial elements in TE?
How to capture these patients in SE?
Should randomisation be a separate visit in
TV/SV?
28
Question 8 – When is a visit no longer
“planned”



Planned visits for lab assessments: Day 15, Day
21
A patient had lab taken on Day 17 and Day 22
instead
Should these be put into planned visits of Day 15
and Day 21, or unscheduled visits?
29
30
Other challenges in oncology studies



Post-remission therapy will be given and patients
will be followed up “according to institution’s
standard treatment practice”
Dose escalation studies – how many arms?
Legacy studies: Do we need to provide trial
design datasets?
31
Summary

Construction of TA/TE/TV
o
o
o
o

Study Schema  Epoch  Arm  Study Cells
Unique study cells = rows in TE
All study cells = rows in TA
If all arms have same visits, then 1 set of visits for all
arms. Otherwise 1 set of visits for each arm.
Complex study designs
o
o
o
Systematic approach will make life easier
Think at protocol/CRF design stage – don’t wait till the
end
Details vs ease of use
32
Thank you!
E-mail: [email protected]
Tel: +44 (0)7904 106966
Web: www.datacision.co.uk

similar documents